Eli Lilly's Retatrutide Shows Over 28% Weight Loss; FDA Approves Extended EBGLYSS Dosing
Summary
Eli Lilly's investigational drug Retatrutide demonstrated an impressive average weight loss of over 28% in an 18-month trial, with a potential regulatory filing and launch anticipated next year. Concurrently, the FDA approved an extended 8-week dosing schedule for Eli Lilly's EBGLYSS for patients aged 12 and older. This news significantly bolsters Eli Lilly's already strong pipeline in the lucrative weight-loss and diabetes markets, building on recent successes with Foundayo and robust financial performance. The strong Retatrutide data indicates another potential blockbuster drug, while the EBGLYSS approval enhances convenience for an existing product.
At the time of this announcement, LLY was trading at $1,144.16 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,182.73. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.